326results about "Microorganism libraries" patented technology

Provided herein are fusion polypeptides comprising an amino acid sequence of a bacteriocin, the amino acid sequence of the bacteriocin being a cleavage intein both on both the N-terminus and on both the C-terminus that cyclizes the bacteriocin. Also provided are nucleic acids and genetic vectors encoding the fusion polypeptides, as well as microbial cells genetically engineered with the nucleic acids or genetic vectors. Also provided are methods of making the cyclic bacteriocin, methods of screening using a library of nucleic acids or genetic vectors encoding the fusion polypeptides, and methods of controlling growth of organisms using the cyclic bacteriocin made by the methods provided herein.

The invention discloses a novel single-cell CRISPR screening library. The invention provides a double-gRNA expression cassette, a double-gRNA expression cassette vector for single-cell CRISPR (clustered regularly interspaced short palindromic repeats) screening and a construction method of a single-cell CRISPR screening library. According to the CRISPR screening library constructed by the method, the single-cell CRISPR screening range can be expanded from a protein coding gene to ncRNA, and the ncRNA can be knocked out.

In traditional plant breeding approaches, chemical mutagenesis may be utilized to introduce nucleotide substitutions at random in the genome of a plant, i.e. without possibilities to control the sites of nucleotide changes. Because of genome complexities, the statistical probability is extremely little when it comes to finding a predetermined nucleotide substitution. The present invention, however, demonstrates how a novel, alternative use of digital polymerase chain reaction (dPCR), preferably droplet dPCR (ddPCR), is developed to exploit finding of specific nucleotide substitutions in mutated genes. The entire platform comprises a screening method with a library of mutagenized organisms, digital PCR-based systems and a set-up to propagate and analyze identified, mutated organisms.

The disclosure relates, inter alia, to a library of transcriptional data, and methods for assembling and using same.

The present disclosure provides a system for expressing a target protein in conjunction with an enhancer protein. The enhancer protein can be a viral protein that blocks nucleocytoplasmic transport. Polynucleotides, vectors, and cells comprising nucleic acid sequences of the target protein and the enhancer protein are also provided. In one aspect, the present disclosure provides a system for recombinantly expressing a target protein in a eukaryotic cell, comprising one or more vectors. The vector(s) comprises a first polynucleotide encoding the target protein and a second polynucleotide encoding the enhancer protein.

A genetic prime editing screening platform to identify functional variants related to human health and disease, is configured substantially to annotate genome with nucleotide resolution with actionable disease prediction and treatment for personalized medicine.

A gene-leader editing screening platform for identifying functional variations associated with human health and disease, substantially configured to annotate genomes with nucleotide resolutions, accompanied by operable disease prediction and treatment for personalized medical treatment.

Provided herein are recombinant adeno-associated virus (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins.

To provide: an antigen binding molecule with enhanced uptake of antigen into cells; an antigen binding molecule with an increased number of bonds to an antigen; an antigen binding molecule which can promote the decrease of antigen concentration in blood plasma when administered; and an antigen binding molecule with improved retention in blood plasma.SOLUTION: An antigen binding molecule comprises an antigen binding domain and a human FcRn binding domain, in which the antigen binding activity under two different calcium concentration conditions is different, the antigen binding activity of the antigen binding molecule under low calcium concentration conditions being lower than antigen binding activity under high calcium concentration conditions, and which has binding activity to human FcRn under neutral pH conditions.SELECTED DRAWING: None

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Rb, compositions comprising such antibodies, and methods of use thereof.

The present invention provides an hBCMA-binding polypeptide comprising at least one motif that binds to hBCMA, wherein the peptide has the following structure: [N-terminal portion]-[Helix 1]-[Spacer portion]-[Helix 2]-[C-terminal portion], and the hBCMA-binding motif is the portion [Helix 1]-[Spacer portion]-[Helix 2]. The present invention further provides a pharmaceutical composition comprising the hBCMA-binding polypeptide, and the use of the hBCMA-binding polypeptide or the pharmaceutical composition for use as a medicament, particularly for the treatment or prevention of cancer.

The present invention relates to a bicyclic peptide complex comprising a peptide construct, the construct comprising: (i) a polypeptide having a free terminus (N or C); (ii) optionally a nucleic acid encoding the polypeptide; and (iii) a dyad-symmetric linker (TSL) compound attached to the polypeptide, wherein the linker is attached to the terminus of the polypeptide and to at least two distinct side chains of the peptide via a covalent bond. The present invention also relates to a library and methods for making the complex, and to screening methods using the same.

The invention belongs to the field of neuroblastoma tissue analysis, and particularly discloses a child neuroblastoma tissue microarray chip and a preparation method thereof.The child neuroblastoma tissue microarray chip comprises a glass slide base material, and a plurality of neuroblastoma tissue samples arranged in a dot-matrix mode are arranged on the glass slide base material; by integrating a plurality of neuroblastoma samples including various pathological typing, grading and clinical staging types of neuroblastoma in a tissue block, efficient sample processing and analysis are achieved, comprehensiveness and representativeness of research are ensured, a large number of samples are analyzed simultaneously through a microarray technology, and the accuracy and accuracy of analysis are improved. The requirements for high-throughput screening of specific genes and expression proteins thereof in scientific research activities are met, the prediction capacity for tumor prognosis and the guidance accuracy for treatment schemes are improved, and neuroblastoma tissues are analyzed more efficiently and comprehensively.

The present disclosure provides a recombinant Salmonella strain having a Type III secretion system (T3SS) comprising mutation which enhance protein expression and production. Additionally, methods and kits for using the recombinant Salmonella strain for producing a protein of interest are provided. Additionally, an optimized medium that increases protein expression in a Salmonella strain having a Type III secretion system (T3SS) is provided.

The present invention provides a method for screening for a candidate peptide capable of binding to a target molecule, the method including the steps of: (1) preparing a plurality of nucleic acid display libraries containing a barcoded peptide-nucleic acid complex, wherein the barcoded peptide-nucleic acid complex contains a nucleic acid moiety and a peptide moiety, the nucleic acid moiety contains a barcode sequence and a nucleic acid sequence encoding the peptide, and the plurality of nucleic acid display libraries are nucleic acid display libraries, each of which is independently produced by translation using a cell-free translation system; (2) mixing the plurality of nucleic acid display libraries to prepare a mixed nucleic acid display library; (3) bringing the mixed nucleic acid display library into contact with the target molecule; and (4) amplifying a nucleic acid corresponding to the nucleic acid moiety of the barcoded peptide-nucleic acid complex bound to the target molecule, using a barcode primer.

The present invention provides a method of constructing a library of binder scaffolds (library of protein scaffolds) comprising the steps a) providing an initial polypeptide, wherein said initial polypeptide comprises or consists of a polypeptide having at least 90% identity to SEQ ID NO:1, and b) introducing diversity into copies of said initial polypeptide to form the binder scaffold library (protein scaffold library).

The present disclosure provides methods for improving libraries for screening protein-protein interactions (PPI) by excluding amino acid substitutions that are predicted to have a redundant or minimal effect on binding between protein binding partners.

The present invention relates to modified amino acid degrons (MAADs) and methods for identifying factors that mediate the selective degradation of MAAD-tagged proteins.

Disclosed are compositions and methods for engineered DLL4 proteins. In one aspect, disclosed herein are engineered DLL4 proteins comprising a conservative amino acid substitution at a residue corresponding to residues 28, 107, 143, 194, and 206 as set forth in SEQ ID NO: 1 and further comprising at least one conservative amino acid substitution at residues 256, 257, 271, 280, 301, and 305 as set forth in SEQ ID NO: 1.

The application discloses a hemoglobin camel-derived nanobody and a preparation method and application thereof. The hemoglobin camel-derived nanobody is an amino acid sequence shown in SEQ ID NO: 7, is a hemoglobin camel-derived nanobody specific to hemoglobin derived from a bactrian camel, has small molecules, can easily penetrate, has high specificity, good stability, is easy to produce and transform, has wide application prospects, and can be applied to the fields of biomedical research, clinical diagnosis and treatment and the like.

The present disclosure relates to a modified polypeptide of glutamine synthetase having enhanced activity and a method of producing L-glutamine using the same. Since production of L-glutamine may be increased by using the novel modified polypeptide without a decrease in a growth rate compared to wild-type strains having glutamine synthetase activity, the modified polypeptide may be widely used for mass production of L-glutamine.

The present disclosure provides methods, compositions, and systems for evolving virus-like particles (VLPs) having one or more desired properties such as increased production levels, increased cargo packaging efficiency, and / or increased transduction of particular target cell types of interest. The present disclosure also provides libraries for use in such methods, and methods for producing the libraries. Group specific antigen (gag) proteins comprising nucleocapsid protein variants evolved using the methods described herein are also provided herein. The present disclosure also provides VLPs comprising such gag proteins comprising nucleocapsid protein variants. Polynucleotides, vectors, cells, and kits useful for performing the methods described herein are also provided.

The present invention provides cell vaccine platforms, such as vaccine-immune virus opsonization platforms, for inducing a host immune response, as well as methods for producing and using such cell vaccine platforms. [Solution] Several embodiments provide genetically engineered human cells comprising (a) genomic disruption in at least one human leukocyte antigen (HLA) gene or at least one transcription regulator of an HLA gene, and (b) an exogenous nucleic acid encoding a cell surface protein that binds to a protein expressed on the surface of phagocytic or cytolytic immune cells, or a functional fragment or functional variant of the cell surface protein, wherein the binding results in activation of the phagocytic or cytolytic activity of the immune cells.

The invention belongs to the technical field of biosynthesis, and discloses a method for improving the yield of valarene by using a saccharomyces cerevisiae rearrangement technology, which comprises the following steps: firstly, constructing a saccharomyces cerevisiae rearrangement strain library by using a synthetic chromosome rearrangement technology; then, the haploid strains in the saccharomyces cerevisiae rearrangement strain library and the valarene haploid production strains are mated to generate diploid valarene production strains; and finally, fermenting the diploid valarene production strain to obtain a valarene product. Fermentation verification is carried out on a diploid ceraene production strain and a haploid ceraene production strain (contrast), and results show that the yield of the ceraene haploid production strain is 163.81 mg / L, the highest yield of the diploid production strain is 194.14 mg / L, the yield is improved by 18.5% compared with that of an original strain, and it is proved that the production capacity of the ceraene is improved through the method.

The present disclosure provides methods and compositions related to modifying Tregs to improve therapeutic efficacy. In some embodiments, modified Tregs are provided by reducing the expression of one or more endogenous target genes or by reducing the function of one or more endogenous proteins to enhance the immunosuppressive function of the immune cells. In some embodiments, Tregs are provided that are further modified by introducing a transgene that confers antigen specificity, such as an exogenous T cell receptor (TCR) or chimeric antigen receptor (CAR). Methods of treating autoimmune diseases using the modified Tregs described herein are also provided.

The invention relates to a new method for selecting or screening antibodies and antigens from an antibody library together with suitable expression vectors and their use.

The invention relates to a bicyclic peptide complex comprising a peptide construct, said construct comprising (i) a polypeptide with free terminus (N or C); (ii) optionally, a nucleic acid encoding the polypeptide; (iii) a twofold-symmetric linker (TSL) compound attached to said polypeptide where the linker is attached to the terminus of polypeptide via a covalent bond and to at least two discrete side chains of the peptide. The invention also relates to libraries, and to methods for making complexes and to methods of screening using the same.

We provide a system for screening compounds. [Solution] This application provides beads with covalently attached compounds and covalently attached DNA barcodes, as well as methods for using such beads. The beads have many substantially identical copies of compounds and many substantially identical copies of DNA barcodes. The compounds consist of one or more chemical monomers, and the DNA barcodes take the form of barcode modules, each module enabling the identification of corresponding and corresponding chemical monomers. The nucleic acid barcodes may have a chain-like or orthogonal structure. Methods for sequencing bead-bound nucleic acid barcodes, methods for cleaving compounds from beads, and methods for evaluating the biological activity of released compounds are provided.

The subject matter of the present disclosure relates to combinatorial vector cloning and transfection strategies for generating targeted integration host cells suitable for expression of recombinant proteins, as well as targeted integration host cells generated by said strategies and compositions comprising said targeted integration host cells.

The present invention relates to a recombinant yeast characterized in that its genome comprises a metabolite-inducible promoter in place of the native promoter of the AGA1 gene, to a plasmid comprising (i) a metabolite-inducible promoter operatively linked the nucleotide sequence coding for a fusion protein comprising a protein of interest, and to the combined use of said yeast and plasmid in a Yeast Surface Display method.